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The Mitroflow aortic pericardial bioprosthesis has been available worldwide since 1982, 
except in the United States, Japan, and China. The original prosthesis was designated model 
11, and the model 12, introduced in 1991, was approved in the United States in November 
2007. The current model Mitroflow LX is available on the worldwide market, except for 
Japan and China. 
The objective of this review is to document the clinical and hemodynamic performance of 
the Mitroflow pericardial bioprosthesis and to document the modifications of the Mitroflow 
LX model and the recently introduced calcium mitigation treatment of pericardial tissue.  
2. Device specifications 
The Mitroflow pericardial bioprosthesis has had three design changes since its introduction 
in 1982 (Figure 1A-J).  
There are the general specifications of all three models of the prosthesis. The prosthesis is 
formulated with a single unit acetal homopolymer stent that provides flexibility and 
strength at implantation without the risk of residual distortion. The stent is low-profile to 
afford clearance of the coronary ostia, and to avoid interfering with the sinotubular junction 
in narrow aortic roots. The stent is also creep resistant. The stent is covered with surgical-
grade polyester cloth and incorporates a tungsten impregnated radiopaque, medical-grade 
silicone sewing ring that is tiny and soft so it can be easily attached to the patient’s tissue 
annulus. The silicone sewing ring also provides a secure hemostatic seal. The pericardium is 
mounted externally to maximize the flow area with wide, synchronous opening of the 
leaflets. The pericardium is used as a single component without critical stent-post sutures. 
The pericardial thickness is related to the size of the prosthesis. The pericardial tissue is 
selected for uniformity, and this tissue is sewn onto the external surface of the covered stent.  
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Fig. 1. (A) Acetyl homopolymer stent. (B) Stent covered polyester cloth. (C) Pericardium 
mounted externally. (D) Silicone sewing ring. (E) Cutaway of Prosthesis. (F) Aortic aspect  
of prosthesis. (G) Aortic aspect leaflets open. (H) Complete prosthesis – titled profile.  
(I) Complete prosthesis – lateral profile. (J) Supra-annular implantation of the prosthesis. 
Model 12 - B,C,F and Model LX - G,H,I 
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The pericardial tissue undergoes leaflet formation in the model 11 and 12 prostheses, and 
then fixation in 0.5% glutaraldehyde. The difference between model 11 and model 12 was 
that the polyester cloth was reversed so that the ribbed side was external rather than 
internal where there was a risk of abrasion. 
The distinctive features of the initial models of the Mitroflow prostheses are inclusive in the 
current LX model. The design features of the various models are important when evaluating 
the current LX model. Model LX is a variation of model 12 with manufacturing 
modifications. The differences between the two models are related to manufacturing 
processes and minor design variations, but the material components remain the same as in 
model 12. The changes are these: because model LX uses automatic machine sewing instead 
of manual sewing for the fabric tube seam in the covered stent, there is a change in the fabric 
orientation of the covered stent. The number of sewing cuff base seams has been reduced to 
one seam. Model LX has changed tissue fixation with 0.2% glutaraldehyde of the bovine 
pericardium from postfixation (after stent application) to prefixation (before stent 
application) to facilitate tissue application on the stent. This change is from a manual leaflet 
formation method to an automated leaflet formation method. These manufacturing process 
improvements for model LX were implemented to increase manufacturing efficiencies, not 
to affect the design or performance of the prosthesis. 
The next major change of the Mitroflow pericardial bioprosthesis is the addition of calcium 
mitigation therapy. Mitroflow models 11 and 12 did not have calcium mitigation therapy 
incorporated in the manufacturing process. The manufacturing processes are to control or 
reduce degeneration of biological tissue, induced by calcification, tissue stress, or both. The 
major contributing factors in the degeneration of biological tissue (porcine or pericardium) 
are considered to be residual aldehydes and the presence of phospholipids. The major 
manufacturers of bioprostheses have used chemical formulations to control one or both of 
these etiologies since the early 1980s. 
The Sorin Group (Milan, Italy and Vancouver, Canada), manufacturer of the Mitroflow 
pericardial bioprosthesis, has recently completed an evaluation of incorporating calcium 
mitigation in the manufacturing process of the prosthesis and received market approval in 
Europe in July 2011 and subsequently in Canada. The Sorin Group has used methodology to 
control residual aldehydes in their other bioprostheses. This methodology is a detoxification 
process post-glutaraldehyde with homocysteic acid to neutralize unbound residual 
aldehydes. The methodology for the Mitroflow bioprosthesis is a chemical solution effective 
in reducing the phospholipid content of bovine pericardium (Figure 2). 
The process has been named phospholipid reduction therapy (PRT), a patented chemical 
process that uses long-chain alcohol aqueous solutions to remove phospholipids from tissue 
materials. The process exposes the bovine pericardium to a buffered ethanolic solution 
containing long-chain aliphatic alcohol for specific times and temperatures. The PRT 
treatment is a sterile-filtered solution of 5% 1,2-Octanediol in ethanol and HEPES solutions. 
An evaluation of 5% 1,2-Octanediol in the rat subcutaneous model has revealed a very 
significant reduction of tissue calcium and phosphorus (Figure 2) (Pettenazzo et al., 2008). 
Incorporating PRT with homocysteic acid aldehyde control therapy is under consideration 
to control both known etiologies of tissue mineralization. 
The Sorin Group (2011) has documented in their product literature the specifications and in 
vitro effective orifice areas (EOA) by valve size. The reported internal diameter/EOA for 
size 19 was 15.4 mm/1.7 cm2; size 21, 17.3 mm/2.1 cm2; size 23, 19.0 mm/2.8 cm2; and size 
25, 21.0 mm/3.2 cm2. 
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Fig. 2. Results of Phospholipid Reduction Therapy (PRT) in subcutaneous rat model 
Pettenazzo et al Eur J Cardiothorac Surg 2008 
3. Implantation technique 
The Mitroflow bioprosthesis can be implanted using either supra-annular or infra-annular 
techniques. The supra-annular technique is preferable to get the largest valve implanted and 
to optimize hemodynamic performance (Figure 1J). The supra-annular positioning facilitates 
a one-to-one annular match and optimal blood flow. The native annulus should be 
adequately debrided for placement of supra-annular suturing. Since the sewing cuff of the 
prosthesis is flat and non-scalloped, it may be optimal on some occasions, especially with 
bicuspid anatomy, to place non-pledgeted everting mattress sutures at the commissures and 
standard non-everting mattress sutures in the remainder of the annulus for supra-annular 
implantation. 
4. Clinical performance 
The clinical performance of the Mitroflow aortic bioprosthesis is comparable to that of other 
marketed porcine and pericardial bioprostheses (Jamieson, 2011). 
The clinical performance of the Mitroflow pericardial bioprosthesis has been reported by 
several investigative groups (Table 1) ( Benhameid et al., 2008; Minami et al., 2005; Yankah 
et al., 2008; Yankah et al., 2010; Jamieson et al., 2009; Alvarez et al., 2009; ISTHMUS 
investigators, 2011; Conte et al., 2010; Jamieson et al., 2009). Actuarial freedom from 
structural valve deterioration provides an assessment of durability while actual cumulative 
incidence analysis documents structural valve deterioration in patient groups, such as 
elderly patients, who are subject to competing risks of death. Actuarial freedom from 
structural valve deterioration (SVD) overestimates the incidence of SVD, while actual 
analysis provides the actual risk of failure in specific population groups. 
Advancing life expectancy with the increased prevalence of aortic valve degenerative disease 
brings the need for an aortic bioprosthesis with excellent hemodynamic performance and 
comparable durability. The University of British Columbia and collaborating centers have  
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published extensively on the Mitroflow pericardial bioprosthesis model 11 (Benhameid et 
al., 2008) and model 12 (Yankah, 2010; ISTHMUS Investigators, 2011, Lorusso, 2011 – 
Personal Communication – ISTHMUS Investigators). 
 
  Mean Age Freedom from SVD (%) Time Interval 
Author Prosthesis Age Group Actuarial Actual (Years) 
Mitroflow  ≥60 85.2 ± 3.9* 93.3 ± 1.8* 12 
  ≥65 85.0 ± 4.0* 94.2 ± 1.8* 12 
  61-70 95.7 ± 4.3* 97.4 ± 2.6* 10 
Jamieson et al. 
(2009) 
  >70 83.2 ± 4.6* 94.0 ± 1.9* 12 
Mitroflow 73.2 ± 0.22     
  ≥65 71.8 ± 6.0* 92.6 ± 4.6* 20 
Yankah et al. 
(2008) 
  ≥70 84.8 ± 0.7* 96.6 ± 0.8* 20 
Mitroflow 75.3 ± 6.8 <60 54.4 ± 3.4 60.9 ± 4.3 18 
  61-70 62.0 ± 2.6 68.3 ± 3.3 18 
  >70 78.2 ± 2.6 89.3 ± 2.5 18 
  <60 75.4 ± 2.9** 87.4 ± 2.3** 18 
  61-70 87.0 ± 1.6** 92.9 ± 0.4** 18 
ISTHMUS 
(2010) 
  >70 94.6 ± 0.6** 97.1 ± 0.5** 18 
* Reoperation,  
** Reoperation, Autopsy & Echocardiography (non-prospective) Lorusso – Personal Communication 2011. 
Table 1. Freedom from Structural Valve Deterioration (SVD) 
Benhameid et al. (2008) reported a satisfactory freedom from SVD after 15 years with model 
11 for patients ≥70 years old. The majority of other publications provide information on the 
freedom from SVD in patient populations with model 11 (predominately) and 12 prostheses 
(Minami et al., 2006; Yankah et al., 2008). These reports provide support for use of the 
prosthesis in elderly patient populations. Yankah et al. (2008), documented in patients with 
predominately model 11 prostheses for 20 years, that freedom from SVD was 71.8 ± 6.0% for 
those ≥65 years old and 84.8 ± 0.7% for those ≥70 years old. Yankah et al. (2010) has since 
reported on 104 patients <60 years old (age range: 22-60 years) with a linearized rate of 
1.9%/patient-year of SVD managed by reoperation with an actual risk of 12% at 10 years. 
Klieverik et al. (2007) concluded that the Mitroflow valve demonstrated an important 
complementary role to allograft and pulmonary autografts if implanted in appropriately 
selected patients. 
The predominant publication on Mitroflow model 12 is Jamieson et al. (2009) (Figure 3A-D). 
This report provides preliminary support for using the prosthesis in patients 61-70 years 
old, as well as in patients >70 years old. The 12-year freedom from SVD (actual/actuarial) at 
explant was 94.4%/85.2% for those ≥60 years old, 94.2%/85.0% for those ≥65 years old, and 
94.0%/83.2% for those >70 years old. For patients 61-70 years old, at 10 years, the freedom 
from SVD at explant was 97.4%/95.7%. 
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(C) 
Fig. 3. Freedom from Structural Valve Deterioration (SVD) at Explant (A) ≥65 years, (B) 65-70 
years, (C) >70 years 
There always remains a concern about the true incidence of SVD unless there is a 
prospective echocardiographic program, because elderly patients may not be evaluated 
for prosthesis failure or presented for reoperation. The results in the 61-70 years old age 
group is encouraging, even though small in number, because patients with a failed 
prosthesis because of SVD in that age group would more likely to be referred for 
reoperative surgery. 
In another recent report on the Mitroflow model 12, Alvarez et al. (2009) reported the 
freedom from SVD by reoperation, as well as the freedom from bioprosthesis 
degeneration determined from prospective echocardiographic assessment. These authors 
report their freedom from SVD at an advanced interval with a minimal number of 
patients at risk. The freedom from SVD at a more appropriate interval seems to be very 
similar to that documented in Jamieson et al. (2009). We believe that because Alvarez et al. 
(2009) did a prospective echocardiographic study, some patients had prophylactic 
reoperative surgery.  
The most extensive published report is the multicenter ISTHMUS study (2011) on 1591 
patients, of which 91% had model 12 prostheses. The study reported on SVD by actuarial 
analysis of echocardiographic diagnoses that used the American Association for Thoracic 
Surgery (AATS), Society of Thoracic Surgeons (STS), and European Association for Cardio-
Thoracic Surgeons (EACTS) guidelines. Personal communication from the ISTHMUS  
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Fig. 4. Freedom from Structural Valve Deterioration (SVD) by clinical relevant symptoms, 
explantation or autopsy. (A) Overall freedom from SVD Actuarial and Actual. (B) Actuarial 
freedom from SVD. (C) Actual freedom (cumulative incidence) from SVD. ISTHMUS 
Investigators – Lorusso (Personal Communication – 2011) 
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authors (R Lorusso) has provided actual documentation incorporating clinical symptoms, 
explantation, echocardiographic examination, and autopsy assessment. The 18-year actual/ 
actuarial freedom from SVD incorporating clinical symptoms, explantation, echocardiographic 
examination and autopsy examination for patients <60 years old was 87.4%/75.4%, for 
patients 61-70 years old was 92.9%/87.0%, and for patients >70 years old was 97.1%/94.6%. 
4. Hemodynamic performance 
The hemodynamic performance of the Mitroflow aortic bioprosthesis is considered excellent 
and very important in optimizing management for the small aortic annulus (Table 2).  
 
 Size 
Author 19 mm 21 mm 23 mm 25 mm 27 mm 
Yankah et al.  
(2008) 
1.4 1.5 1.85   
Jamieson et al.  
(2009) 
1.4 1.4 1.8 1.8  
Conte et al.  
(2010) 
1.05 1.22 1.37 1.60 1.82 
Table 2. Hemodynamic Orifice Areas (cm2) for Mitroflow Aortic Bioprostheses 
These three studies show excellent hemodynamic performance of the prosthesis. Jamieson et 
al. (2009) reported that the in vivo effective orifice areas by valve size provide the 
opportunity of avoiding obstructive characteristics for all valve sizes, including optimizing 
the management of the small aortic annulus. The EOA for the 19-mm and 21-mm prostheses 
is 1.4 cm2, and for the 23-mm and 25-mm prostheses is 1.8 cm2. These EOAs in the 
population reported prevented prosthesis-patient mismatch in all valve sizes with indexed 
EOAs ranging from 0.8 to 1.0 cm2/m2. 
In their study on the hemodynamic performance of 1513 isolated aortic valve replacements, 
primarily model 11, Yankah et al. (2008) reported that the EOA for size 19-mm prosthesis 
was 1.4 cm2; the 21-mm, 1.5 cm2; and the 23-mm, 1.85 cm2. 
The Conte et al. (2010) study of the Mitroflow model 12 prosthesis reported very satisfactory 
hemodynamic performance. The effective orifice areas for the 19-mm prosthesis was 1.05 cm2; 
the 21-mm, 1.22 cm2; the 23-mm, 1.37 cm2; the 25-mm, 1.60 cm2; and the 27-mm, 1.82 cm2. 
The mean gradient for the 19-mm prosthesis was 13.4mm Hg.; the 21-mm, 11.5mm Hg.; the 
23-mm, 10.6mm Hg.; the 25-mm, 8.6mm Hg.; and 27-mm, 7.3mm Hg. 
The Mitroflow LX external mounted pericardial bioprosthesis will continue to provide 
optimization of hemodynamics regardless of valve size, especially in the small aortic 
annulus. The addition of anticalcification therapy to the manufacturing process will provide 
the opportunity to retard or prevent structural valve deterioration of the bioprosthesis and 
may improve its long-term durability; this prosthesis has clinically been shown to be 
comparable in durability to other bovine pericardial aortic bioprostheses (Jamieson et al., 
2009; Alvarez et al., 2009; ISTHMUS Investigators, 2011). 
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